{"schema_version":"secwatch.filing_event.v1","accession":"0001412408-21-000090","form_type":"8-K","ticker":"PHR","cik":"0001412408","company_name":"Phreesia, Inc.","filed_at":"2021-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.446345+00:00","generated_at":"2026-06-28T02:47:05.814562+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Phreesia Q3 revenue $55.9M (+45% YoY); FY22 outlook raised to $211M","bullets":["Revenue $55.9M, up 45% YoY; net loss $36.3M ($0.71/share) vs $6.7M loss prior year.","Adjusted EBITDA -$17.6M vs +$1.2M a year ago, reflecting increased growth investment.","FY2022 revenue outlook raised to $211M from $195-198M; FY2023 growth guided 20-25%.","Cash $400.4M after follow-on offering generating $245.8M net proceeds.","Agreed to acquire Insignia Health for $35M cash; adds Patient Activation Measure (PAM)."],"urls":{"canonical":"https://secwatch.observer/filing/0001412408-21-000090","json":"https://secwatch.observer/filing/0001412408-21-000090.json","markdown":"https://secwatch.observer/filing/0001412408-21-000090.md","text":"https://secwatch.observer/filing/0001412408-21-000090.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412408/000141240821000090/0001412408-21-000090-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412408/000141240821000090/phr-20211208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T02:47:05.814562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}